BioCentury | Nov 23, 2015
Clinical News

CardioCel regulatory update

...ADAPT tissue engineering process. CardioCel is available in the U.S. and has CE Mark approval. Admedus Ltd....
BioCentury | Apr 27, 2015
Clinical News

HSV-2 vaccine: Phase II started

...booster injection at 6 months in 40 HSV-2-infected patients ages 18-50 who are otherwise healthy. Admedus...
BioCentury | Mar 23, 2015
Financial News

Admedus completes placing

Admedus Ltd. (ASX:AHZ), Perth, Australia Business: Transplant, Infectious Date completed: 2015-03-18 Type: Placing Raised: A$12 million ($9.2 million) Shares: 171.5 million Price: A$0.07 Shares after offering: 1.6 billion Investor: Institutional investors WIR Staff Infectious Transplant...
BioCentury | Mar 23, 2015
Financial News

Admedus proposes rights offering

Admedus Ltd. (ASX:AHZ), Perth, Australia Business: Transplant, Infectious Date announced: 2015-03-18 Type: Rights offering To be raised: Up to A$16.1 million ($12.3 million) Shares: 230.6 million Price: A$0.07 Shares outstanding prior: 1.6 billion Investor: Existing...
BioCentury | Nov 3, 2014
Clinical News

CardioCel regulatory update

...Health Canada approved Admedus' CardioCel to repair congenital heart deformities and more complex heart defects. CardioCel...
...CE Mark approval. It is available in Australia under the early access Authorised Prescriber scheme. Admedus Ltd....
BioCentury | May 19, 2014
Financial News

Admedus completes private placement

Admedus Ltd. (ASX:AHZ), Perth, Australia Business: Transplant, Infectious Date completed: 5/12/14 Type: Private placement Raised: A$8 million ($7.5 million) Shares: 80 million Price: A$0.10 Shares after offering: 1.3 billion Placement agents: Morgans; WG Partners; Baillieu...
BioCentury | Feb 24, 2014
Clinical News

CardioCel patch regulatory update

...FDA granted 510(k) clearance for Admedus' CardioCel patch for pericardial closure and repair of cardiac and...
...pericardium using the company's ADAPT Tissue Engineering Process has CE Mark approval in the EU. Admedus Ltd....
BioCentury | Feb 17, 2014
Clinical News

HSV-2 vaccine: Interim Phase I data

...Interim data from a Phase I trial showed that Admedus' HSV-2 vaccine was safe and generated...
...and generated a T cell response. The company declined to disclose details or next steps. Admedus Ltd....
BioCentury | Apr 15, 2013
Clinical News

CardioCel patch: Pilot trial started

...years. The company said it expects a decision by mid-year on CE Mark of CardioCel. Allied Healthcare...
BioCentury | Dec 24, 2012
Financial News

Allied Healthcare proposes private placement

Allied Healthcare Group Ltd. (ASX:AHZ), Perth, Australia Business: Transplant, Supply/Service Date announced: 12/17/12 Type: Private placement To be raised: TBD Shares: TBD Price: A$0.02 Placement agent: RBS Morgans Shares outstanding prior: 890.4 million Investors: Existing...
Items per page:
1 - 10 of 14
BioCentury | Nov 23, 2015
Clinical News

CardioCel regulatory update

...ADAPT tissue engineering process. CardioCel is available in the U.S. and has CE Mark approval. Admedus Ltd....
BioCentury | Apr 27, 2015
Clinical News

HSV-2 vaccine: Phase II started

...booster injection at 6 months in 40 HSV-2-infected patients ages 18-50 who are otherwise healthy. Admedus...
BioCentury | Mar 23, 2015
Financial News

Admedus completes placing

Admedus Ltd. (ASX:AHZ), Perth, Australia Business: Transplant, Infectious Date completed: 2015-03-18 Type: Placing Raised: A$12 million ($9.2 million) Shares: 171.5 million Price: A$0.07 Shares after offering: 1.6 billion Investor: Institutional investors WIR Staff Infectious Transplant...
BioCentury | Mar 23, 2015
Financial News

Admedus proposes rights offering

Admedus Ltd. (ASX:AHZ), Perth, Australia Business: Transplant, Infectious Date announced: 2015-03-18 Type: Rights offering To be raised: Up to A$16.1 million ($12.3 million) Shares: 230.6 million Price: A$0.07 Shares outstanding prior: 1.6 billion Investor: Existing...
BioCentury | Nov 3, 2014
Clinical News

CardioCel regulatory update

...Health Canada approved Admedus' CardioCel to repair congenital heart deformities and more complex heart defects. CardioCel...
...CE Mark approval. It is available in Australia under the early access Authorised Prescriber scheme. Admedus Ltd....
BioCentury | May 19, 2014
Financial News

Admedus completes private placement

Admedus Ltd. (ASX:AHZ), Perth, Australia Business: Transplant, Infectious Date completed: 5/12/14 Type: Private placement Raised: A$8 million ($7.5 million) Shares: 80 million Price: A$0.10 Shares after offering: 1.3 billion Placement agents: Morgans; WG Partners; Baillieu...
BioCentury | Feb 24, 2014
Clinical News

CardioCel patch regulatory update

...FDA granted 510(k) clearance for Admedus' CardioCel patch for pericardial closure and repair of cardiac and...
...pericardium using the company's ADAPT Tissue Engineering Process has CE Mark approval in the EU. Admedus Ltd....
BioCentury | Feb 17, 2014
Clinical News

HSV-2 vaccine: Interim Phase I data

...Interim data from a Phase I trial showed that Admedus' HSV-2 vaccine was safe and generated...
...and generated a T cell response. The company declined to disclose details or next steps. Admedus Ltd....
BioCentury | Apr 15, 2013
Clinical News

CardioCel patch: Pilot trial started

...years. The company said it expects a decision by mid-year on CE Mark of CardioCel. Allied Healthcare...
BioCentury | Dec 24, 2012
Financial News

Allied Healthcare proposes private placement

Allied Healthcare Group Ltd. (ASX:AHZ), Perth, Australia Business: Transplant, Supply/Service Date announced: 12/17/12 Type: Private placement To be raised: TBD Shares: TBD Price: A$0.02 Placement agent: RBS Morgans Shares outstanding prior: 890.4 million Investors: Existing...
Items per page:
1 - 10 of 14